What FBC findings should prompt a same-day call to haematology?

Same-day haematology referral is warranted for pancytopenia (low red cells, white cells, and platelets together); any circulating blasts on the blood film; neutrophil count below 0.5 × 10⁹/L with fever (febrile neutropenia, a medical emergency); platelets below 20 × 10⁹/L with active bleeding or petechiae; white cell count above 100 × 10⁹/L with neurological or respiratory symptoms (leukostasis). Phone the lab, name the clinical suspicion on the request form, and ask for specific microscopist review. Auer rods in the cytoplasm are pathognomonic for AML. Smear cells are characteristic of CLL.

What is acute promyelocytic leukaemia (APL) and why is it special?

Acute promyelocytic leukaemia (APL, AML-M3) is caused by the t(15;17) PML::RARA fusion. It is treated as a separate emergency because it presents with simultaneous disseminated intravascular coagulation (DIC) and hyperfibrinolysis — the dominant early cause of death is haemorrhage, not infection. Any young adult with circulating promyelocytes on a blood film and coagulopathy should receive all-trans retinoic acid (ATRA) on clinical suspicion without waiting for cytogenetics confirmation. APL has the highest cure rate of all AML subtypes when treated promptly, approaching over 90% in standard-risk disease.

What does watch-and-wait mean for CLL?

Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia and is frequently discovered incidentally on a routine FBC. The clonal B-cell count is above 5 × 10⁹/L by definition. For early-stage, asymptomatic CLL, international guidelines and the iwCLL 2018 consensus confirm that early treatment offers no survival benefit over observation. Watch-and-wait means regular FBC and examination every three months initially, looking for progressive cytopenias, bulky lymphadenopathy, B-symptoms (fever, night sweats, weight loss), or lymphocyte doubling time under six months. Treatment is started when any of these appear, not on diagnosis alone.

How has treatment for chronic myeloid leukaemia changed survival?

CML is defined by the BCR::ABL1 fusion gene (Philadelphia chromosome, t(9;22)) and was historically a disease with median survival of three to five years. The introduction of imatinib (Gleevec) in 2001, reported in the landmark IRIS trial with long-term follow-up by Hochhaus in NEJM 2017, transformed CML into a near-normal life expectancy condition for the majority of patients in chronic phase. Second and third generation tyrosine kinase inhibitors — dasatinib, nilotinib, bosutinib, ponatinib, and asciminib — provide options for resistance, intolerance, or high-risk disease. Around 40–50% of patients achieving sustained deep molecular remission can attempt treatment cessation.

What should general practitioners do for leukaemia patients between haematology appointments?

In the shared-care model, general practice manages: fever surveillance and rapid antibiotic referral for febrile neutropenia; immunisation using the ATAGI immunocompromised schedule (inactivated vaccines only while on active treatment — live vaccines are contraindicated); skin cancer surveillance after prolonged immunosuppression; cardiovascular risk monitoring (especially on nilotinib, ponatinib, and dasatinib for CML); mental health and cancer-related distress; medication reconciliation for drug interactions (grapefruit and St John's wort both significantly affect TKI levels); nutrition and exercise referral via GP chronic disease management; and advance care planning.

Leukaemia

Leukaemia: recognition and workup — the AU general practice approach

By Dr HB Lo, FACRRM Reviewed 21 August 2026 8 min read

Leukaemia causes approximately 5,000 new Australian diagnoses each year. The general practice role is rapid recognition — acute leukaemia (AML, ALL) is a haematological emergency requiring same-day haematology referral when pancytopenia, circulating blasts, or febrile neutropenia are present.

The four main types differ in urgency. CLL is often an incidental FBC finding managed with watch-and-wait. CML carries near-normal life expectancy on tyrosine kinase inhibitors. After diagnosis, general practice provides shared survivorship care: infection prevention, immunisation, medication reconciliation, and psychosocial support.

Leukaemia is a clonal expansion of haematopoietic precursors in the bone marrow and blood. It is not a single disease — it spans from haematological emergencies requiring same-day treatment to indolent conditions appropriate for years of observation. Understanding this spectrum is the key to the general practice role: recognise quickly, refer appropriately, and then provide ongoing supportive care and cancer survivorship shared care.

The AIHW Cancer Data in Australia 2024 records approximately 5,000 new leukaemia cases annually in Australia. Leukaemia is the sixth most common cause of cancer death nationally. Childhood leukaemia (mostly ALL) is the commonest childhood malignancy, with five-year survival now approaching 90%.

A. Core clinical — the AU general-practice framework

Four main types

Type	Onset	Epidemiology (AU)	Urgency
AML (acute myeloid)	Days to weeks	~1,200/yr; median age 68	Same-day emergency
ALL (acute lymphoblastic)	Days to weeks	~400/yr; bimodal: children 2–5 + adults >50	Same-day emergency
CLL (chronic lymphocytic)	Months or incidental FBC	~1,800/yr; median age 70; commonest adult leukaemia	Within 1 week for stable; watch-and-wait common
CML (chronic myeloid)	Often insidious	~350/yr; median age 60; defined by BCR::ABL1	Within 1 week; near-normal life expectancy on TKI

Symptoms to recognise

The classic bone-marrow-failure triad:

Anaemia: fatigue, pallor, dyspnoea on exertion
Thrombocytopenia: bruising, petechiae, epistaxis, gum bleeding
Neutropenia: recurrent or severe infections

Plus infiltration signs: lymphadenopathy, hepatosplenomegaly, bone pain (especially in paediatric ALL — sternal and long-bone tenderness), gum hypertrophy (AML M4/M5), skin nodules (leukaemia cutis)

Constitutional B-symptoms: fever above 38°C, drenching night sweats, unintentional weight loss above 10% in six months

Emergency red flags requiring same-day action:

Pancytopenia on FBC
Circulating blasts on film
Fever plus neutrophils below 0.5 × 10⁹/L (febrile neutropenia = sepsis emergency)
Platelets below 20 × 10⁹/L with active bleeding
WBC above 100 × 10⁹/L with neurological or respiratory symptoms (leukostasis)
Young adult with bleeding, DIC, and promyelocytes on film — suspected APL: start ATRA on suspicion before cytogenetics

History

Symptom timeline: acute presentations evolve over weeks; CLL and CML may be symptomless
Bone-marrow-failure symptoms: fatigue, dyspnoea on exertion, bruising, epistaxis, gum bleeding, recurrent or severe infection
B-symptoms: fever, drenching night sweats, weight loss
Lymph-node or spleen enlargement: early satiety, abdominal fullness, swelling in neck, axilla, or groin
CNS symptoms: headache, visual changes, cranial-nerve palsy, altered consciousness
Leukostasis symptoms: confusion, shortness of breath with very high white-cell count
Risk factors: prior chemotherapy or radiation (therapy-related AML), Down syndrome, Fanconi anaemia, Li-Fraumeni syndrome, NF1, prior myelodysplastic syndrome or myeloproliferative neoplasm, heavy benzene or petrochemical exposure, prior smoking (modest AML risk), HTLV-1 in ATSI communities in northern Australia

Examination

General: pallor, jaundice (haemolytic anaemia in CLL), fever, weight, ECOG performance status
Skin: petechiae, ecchymoses, purpura, leukaemia cutis (firm violaceous nodules), Sweet’s syndrome in AML
Lymph nodes: all groups — cervical, axillary, supraclavicular, epitrochlear, inguinal — size, consistency, mobility
Abdomen: splenomegaly (often massive in CML), hepatomegaly
Mouth: gum hypertrophy (AML M4/M5), mucositis, oral candidiasis
Bone tenderness: sternum and long bones — classic in paediatric ALL
Cardiorespiratory: tachycardia from anaemia, tachypnoea from leukostasis or infection
Neurological: cranial-nerve palsies, focal deficit — CNS leukaemia

Investigations — GP-initiated

Phone the pathology laboratory and name the clinical suspicion on the request form. Ask for specific microscopist review of the blood film.

First-line (day 0):

FBC with differential and blood film: the cornerstone — look for blasts (AML/ALL), Auer rods (AML, pathognomonic), faggot cells (APL), smear cells (CLL), basophilia plus left shift (CML)
Urea, electrolytes, creatinine, eGFR, LFTs, LDH, urate, calcium, phosphate, magnesium: baseline and tumour lysis risk markers
Coagulation (INR, APTT, fibrinogen, D-dimer): mandatory — exclude DIC, especially if APL is suspected
Group and hold if bleeding or pre-procedure
Pregnancy test in any woman of reproductive age
HIV, HBV, HCV serology: pre-chemotherapy baseline

Specialist-led (not GP-ordered): bone marrow aspirate and trephine, flow cytometry, cytogenetics, molecular panel (FLT3, NPM1, BCR::ABL1, IDH1/2, TP53), CSF cytology, HLA typing.

MBS items: standard consults 23 / 36 / 44; FBC 65070; LDH 66660; immunoglobulins 71161; HIV 69384; HBV 69437.

B. Disease-specific treatment overview — GP awareness

Per ELN 2022, iwCLL 2018, ESMO CML 2024, eviQ, and eTG haematology:

ALL: paediatric protocols (BFM-based) achieve >85% cure rates. Adult ALL uses intensive induction with vincristine, corticosteroid, asparaginase, and anthracycline, plus a tyrosine kinase inhibitor for Ph-positive disease. CNS-directed therapy (intrathecal chemotherapy) is universal. CAR-T therapy (tisagenlecleucel, PBS Authority Section 100) is available for relapsed or refractory paediatric and young adult B-ALL.

AML: standard “7+3” cytarabine plus anthracycline induction, then consolidation (high-dose cytarabine), then allogeneic stem cell transplantation for intermediate and adverse-risk disease. FLT3-mutated AML adds midostaurin per the RATIFY trial (Stone NEJM 2017), PBS Authority Section 100. Venetoclax plus azacitidine (VIALE-A) is PBS-listed for older or unfit patients. APL (AML-M3) — ATRA plus arsenic trioxide achieves >90% cure rates in standard-risk disease per APL0406 (Lo-Coco NEJM 2013).

CLL: watch-and-wait for early asymptomatic disease — no treatment survival benefit (iwCLL 2018). First-line treatment options now include continuous BTK inhibitors (ibrutinib — RESONATE-2 Burger NEJM 2015; acalabrutinib; zanubrutinib — all PBS Authority Section 100) and fixed-duration venetoclax plus obinutuzumab (CLL14 Fischer NEJM 2019, PBS Authority Section 100).

CML: lifelong tyrosine kinase inhibitor (imatinib, dasatinib, nilotinib, bosutinib, ponatinib, or asciminib — all PBS Authority Section 100 Highly Specialised Drugs) has transformed CML to near-normal life expectancy for most patients in chronic phase, as demonstrated by the IRIS long-term follow-up (Hochhaus NEJM 2017) and supported by ESMO CML 2024. Treatment-free remission is achievable in approximately 40–50% who achieve sustained deep molecular remission.

C. General practice supportive role

Infection management: Febrile neutropenia (fever ≥38°C with neutrophils <0.5 × 10⁹/L) is a medical emergency — arrange same-day hospital presentation. The Leukaemia Foundation Australia provides the Blood Cancer Information Helpline (1800 620 420) and a 24/7 fever alert system.

Immunisation: Follow the ATAGI immunocompromised schedule. Live vaccines are contraindicated during active chemotherapy, biologics, and for at least two years post-allogeneic stem cell transplantation. Use recombinant Shingrix (not live Zostavax) for zoster prevention. Annual influenza and COVID-19 boosters, Prevenar 20 followed by PPV23, and pneumococcal catch-up should be offered at appropriate intervals.

Drug interactions: Several leukaemia treatments have clinically significant interactions relevant to general practice prescriptions. Grapefruit and pomelo inhibit CYP3A4 and can significantly raise TKI, venetoclax, and BTK inhibitor levels. St John’s wort induces CYP3A4 and lowers TKI and many other drug levels — this interaction should be explicitly raised at every shared-care appointment.

Cardiotoxicity surveillance: Anthracycline exposure creates long-term left ventricular systolic dysfunction risk. Baseline echocardiogram before treatment and scheduled surveillance imaging at 1, 5, and 10 years post-treatment, or more frequently if symptomatic, is standard survivorship care. Nilotinib and ponatinib (CML TKIs) carry cardiovascular risk including peripheral arterial disease, myocardial infarction, and stroke — optimise all modifiable cardiovascular risk factors.

D. Australian operations

PBS Authority Section 100 Highly Specialised Drugs (all specialist-initiated): imatinib, dasatinib, nilotinib, bosutinib, ponatinib, asciminib (CML); ibrutinib, acalabrutinib, zanubrutinib, venetoclax (CLL); midostaurin, gilteritinib, ivosidenib, enasidenib, venetoclax + azacitidine (AML); tisagenlecleucel, blinatumomab, inotuzumab (ALL); ATRA and arsenic trioxide (APL).

GP-accessible PBS: allopurinol (TLS prophylaxis, general schedule); TMP-SMX (PJP prophylaxis, Authority Streamlined); valaciclovir and aciclovir (HSV/VZV prophylaxis, Authority Streamlined); inactivated influenza vaccine (NIP-funded).

National Blood Authority: Immunoglobulin replacement for symptomatic CLL-related hypogammaglobulinaemia requires authority via blood.gov.au.

GP Chronic Disease Management Plan item 965: Active leukaemia and post-treatment survivorship qualify. Allied health referrals under GPCCMP include dietitian (malnutrition screening, food-safety counselling for neutropenia), exercise physiologist (maintaining muscle mass and reducing fatigue), psychologist (cancer distress, adjustment disorder), and social work (financial toxicity, Leukaemia Foundation peer support).

Mental Health Care Plan item 2715: Cancer-related distress, adjustment disorder, and treatment-related cognitive impairment (“chemo-brain”) are common and respond to psychologist-delivered interventions.

Cancer notifications: Leukaemia diagnosis is notifiable to state cancer registries — this is laboratory-initiated, not a GP responsibility. Advance care planning and enduring power of attorney should be raised at diagnosis, particularly in older patients with AML.

E. Special populations

Older adults and frailty: Median AML age is 68 years — many patients are not fit for intensive chemotherapy. The venetoclax plus azacitidine VIALE-A regimen is approved specifically for older or unfit AML patients and represents a meaningful advance in this population. Comprehensive geriatric assessment, ECOG performance status, and organ-function review inform treatment selection.

Children: Paediatric ALL is the commonest childhood cancer and is curable in over 85% of Australian children through the Australia New Zealand Children’s Haematology/Oncology Group (ANZCHOG) protocols. Referral to a specialist paediatric oncology centre (RCH Melbourne, Westmead, PMH Perth, Women’s and Children’s Adelaide) should be immediate. Long-term survivorship includes monitoring for treatment-related cardiac, endocrine, neurocognitive, and secondary-malignancy effects.

ATSI patients: HTLV-1 is endemic in some Aboriginal communities in northern Australia and is the cause of Adult T-cell leukaemia/lymphoma (ATLL). Screening is appropriate in ATSI patients from endemic regions presenting with unexplained lymphadenopathy, leukaemia, or lymphoma. Engage Aboriginal Liaison Officers at diagnosis; support family and community involvement in care decisions.

When to escalate

Same-day / ambulance: pancytopenia, circulating blasts, febrile neutropenia (fever plus neutrophils <0.5), suspected APL (DIC plus young adult plus bleeding), WBC above 100 × 10⁹/L with leukostasis, platelets below 20 × 10⁹/L with active bleeding.

Within 1 week: isolated unexplained cytopenia with suspicious film, sustained lymphocytosis above 10 × 10⁹/L in stable patient, B-symptoms with lymphadenopathy, painless lymphadenopathy above 4 weeks without infection.

Routine: known CLL on surveillance, post-treatment survivorship shared care, MGUS surveillance.

What this article is and is not

This is general health information drawn from current Australian and international guidelines — AIHW, Therapeutic Guidelines, eviQ, ATAGI, WHO 2022, ELN 2022, iwCLL 2018, and ESMO CML 2024 — for educational purposes. It does not constitute personal medical advice and does not create a doctor–patient relationship. All treatment decisions, including chemotherapy, immunotherapy, and transplant assessment, are made by specialist haematologists in consultation with the patient.

For Australian patient and carer support: Leukaemia Foundation Australia — 1800 620 420 · Cancer Council Australia — 13 11 20 · HealthDirect · Better Health Channel.

Sources cited

Frequently asked questions

What FBC findings should prompt a same-day call to haematology?

Same-day haematology referral is warranted for pancytopenia (low red cells, white cells, and platelets together); any circulating blasts on the blood film; neutrophil count below 0.5 × 10⁹/L with fever (febrile neutropenia, a medical emergency); platelets below 20 × 10⁹/L with active bleeding or petechiae; white cell count above 100 × 10⁹/L with neurological or respiratory symptoms (leukostasis). Phone the lab, name the clinical suspicion on the request form, and ask for specific microscopist review. Auer rods in the cytoplasm are pathognomonic for AML. Smear cells are characteristic of CLL.
What is acute promyelocytic leukaemia (APL) and why is it special?

Acute promyelocytic leukaemia (APL, AML-M3) is caused by the t(15;17) PML::RARA fusion. It is treated as a separate emergency because it presents with simultaneous disseminated intravascular coagulation (DIC) and hyperfibrinolysis — the dominant early cause of death is haemorrhage, not infection. Any young adult with circulating promyelocytes on a blood film and coagulopathy should receive all-trans retinoic acid (ATRA) on clinical suspicion without waiting for cytogenetics confirmation. APL has the highest cure rate of all AML subtypes when treated promptly, approaching over 90% in standard-risk disease.
What does watch-and-wait mean for CLL?

Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia and is frequently discovered incidentally on a routine FBC. The clonal B-cell count is above 5 × 10⁹/L by definition. For early-stage, asymptomatic CLL, international guidelines and the iwCLL 2018 consensus confirm that early treatment offers no survival benefit over observation. Watch-and-wait means regular FBC and examination every three months initially, looking for progressive cytopenias, bulky lymphadenopathy, B-symptoms (fever, night sweats, weight loss), or lymphocyte doubling time under six months. Treatment is started when any of these appear, not on diagnosis alone.
How has treatment for chronic myeloid leukaemia changed survival?

CML is defined by the BCR::ABL1 fusion gene (Philadelphia chromosome, t(9;22)) and was historically a disease with median survival of three to five years. The introduction of imatinib (Gleevec) in 2001, reported in the landmark IRIS trial with long-term follow-up by Hochhaus in NEJM 2017, transformed CML into a near-normal life expectancy condition for the majority of patients in chronic phase. Second and third generation tyrosine kinase inhibitors — dasatinib, nilotinib, bosutinib, ponatinib, and asciminib — provide options for resistance, intolerance, or high-risk disease. Around 40–50% of patients achieving sustained deep molecular remission can attempt treatment cessation.
What should general practitioners do for leukaemia patients between haematology appointments?

In the shared-care model, general practice manages: fever surveillance and rapid antibiotic referral for febrile neutropenia; immunisation using the ATAGI immunocompromised schedule (inactivated vaccines only while on active treatment — live vaccines are contraindicated); skin cancer surveillance after prolonged immunosuppression; cardiovascular risk monitoring (especially on nilotinib, ponatinib, and dasatinib for CML); mental health and cancer-related distress; medication reconciliation for drug interactions (grapefruit and St John's wort both significantly affect TKI levels); nutrition and exercise referral via GP chronic disease management; and advance care planning.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.